Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Wave Life Sciences (WVE) EBITDA (2016 - 2025)

Wave Life Sciences' EBITDA history spans 11 years, with the latest figure at -$53.2 million for Q4 2025.

  • For Q4 2025, EBITDA fell 282.64% year-over-year to -$53.2 million; the TTM value through Dec 2025 reached -$204.4 million, down 110.37%, while the annual FY2025 figure was -$204.4 million, 110.37% down from the prior year.
  • EBITDA reached -$53.2 million in Q4 2025 per WVE's latest filing, up from -$53.9 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $29.2 million in Q4 2024 to a low of -$61.7 million in Q3 2024.
  • Average EBITDA over 5 years is -$32.2 million, with a median of -$38.3 million recorded in 2021.
  • The largest YoY upside for EBITDA was 279.96% in 2024 against a maximum downside of 954.02% in 2024.
  • A 5-year view of EBITDA shows it stood at -$34.9 million in 2021, then decreased by 25.11% to -$43.6 million in 2022, then surged by 62.86% to -$16.2 million in 2023, then skyrocketed by 279.96% to $29.2 million in 2024, then tumbled by 282.64% to -$53.2 million in 2025.
  • Per Business Quant, the three most recent readings for WVE's EBITDA are -$53.2 million (Q4 2025), -$53.9 million (Q3 2025), and -$50.4 million (Q2 2025).